Literature DB >> 16305638

The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome.

P Szodoray1, R Jonsson.   

Abstract

Systemic autoimmune diseases, such as Sjögren's syndrome (SS), are characterized by a complex aetiology with multiple pathogenic factors. In SS, disturbed B-cell biology and humoral immunity including B-cell-activating factor (BAFF)-mediated processes have been described. Dysregulated BAFF expression has been described to lead to disease progression and perpetuation of humoral autoimmunity. Moreover, BAFF has been proposed to contribute to the development of B-cell malignancies. In this review, we summarize the current knowledge on BAFF with regard to SS pathology and discuss special features such as germinal centre (GC) formation and lymphomagenesis. Locally, in SS salivary glands, the reduced level of apoptosis among BAFF-expressing cells might lead to longer-existing BAFF expression and thereby maintain signalling for tissue-infiltrating B cells to proliferate and supposedly to become autoantibody-producing plasma cells. We assume that prolonged BAFF signalization may contribute to GC formation and/or lymphoma development in the disease. Finally, we discuss possibilities of novel treatments targeting the BAFF-system in SS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305638     DOI: 10.1111/j.1365-3083.2005.01688.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  25 in total

Review 1.  Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.

Authors:  B M Lodde; B J Baum; P P Tak; G Illei
Journal:  Ann Rheum Dis       Date:  2006-07-31       Impact factor: 19.103

2.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

Review 3.  Animal models of Sjögren's syndrome.

Authors:  Malin V Jonsson; Nicolas Delaleu; Roland Jonsson
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

4.  TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.

Authors:  J L Vosters; N Roescher; G G Illei; J A Chiorini; P P Tak
Journal:  Oral Dis       Date:  2011-12-29       Impact factor: 3.511

5.  B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.

Authors:  Peipei Zhang; Xiaojing Liu; Aili Guo; Jing Xiong; Yu Fu; Kaifang Zou
Journal:  Dig Dis Sci       Date:  2016-04-07       Impact factor: 3.199

6.  Polymerase chain reaction (PCR) detection of B cell clonality in Sjögren's syndrome patients: a diagnostic tool of clonal expansion.

Authors:  L M Guzmán; D Castillo; S O Aguilera
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

Review 7.  Spontaneous germinal centers and autoimmunity.

Authors:  Phillip P Domeier; Stephanie L Schell; Ziaur S M Rahman
Journal:  Autoimmunity       Date:  2017-02       Impact factor: 2.815

8.  High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia.

Authors:  Xiao-juan Zhu; Yan Shi; Jian-zhi Sun; Ning-ning Shan; Jun Peng; Cheng-shan Guo; Ping Qin; Ming Hou
Journal:  J Clin Immunol       Date:  2009-06-05       Impact factor: 8.317

9.  Signaling pathways for B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in human placenta.

Authors:  Daudi L Langat; David A Wheaton; Jeralyn Sue Platt; Travis Sifers; Joan S Hunt
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

10.  High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency.

Authors:  Adina K Knight; Lin Radigan; Thomas Marron; Allison Langs; Li Zhang; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2007-06-07       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.